Polish authorities have finally decided to reimburse two disease modifying drugs for MS. Dimethyl fumarate and peginterferon beta-1a have been on the market for some time, but were inaccessible to people with MS in Poland. The Polish MS Society has been working really hard to change this.
As part of their World MS Day celebrations, the Polish MS Society held a day of talks and information-giving at the Polish Parliament. In June, they met with the Polish Health Minister and the Prime Minister’s office to discuss the issue of reimbursement. They also met the Head of the Prevention and Rehabilitation Department of the Social Insurance Institution to discuss how proper rehabilitation can help people with MS to stay in work for longer and to lead a more full and active life generally.
In July this year, the good news came that the decision had been made to reimburse dimethyl fumarate and peginterferon. This is a great step forward and will have a positive impact on people with MS in Poland.